
WDN:SLR 09/03/02 137151.doc PATENT



mammalian 13 kDa selenoprotein is reduced by at least 3-fold in the cell of the subject when compared to expression of the 15 kDa selenoprotein in a control cell.

53. (Amended) The method of claim 51, wherein determining the reduced expression of the mammalian 15 kDa selenoprotein comprises determining whether the expression of the mammalian 15 kDa selenoprotein is reduced by at least 50% in the cell of the subject when compared to expression of the 15 kDa selenoprotein in a control cell.

55. (Amended) The method of claim 51, wherein the mammalian 15 kDa selenoprotein has at least 90% sequence identity to SEQ ID NO: 1 or 4.

60. (Amended) The method of claim 51, wherein the cancer is selected from the group consisting of prostate cancer, liver cancer, head and neck cancers, and colon cancer.


63. (Amended) The method of claim 51, wherein the 15 kDa selenoprotein has at least 95% sequence identity to SEQ ID NO: 1 or 4.

64. (Amended) The method of claim 51, wherein the 15 kDa selenoprotein comprises SEQ ID NO: 1 or 4.

Please add the following new claims:

- 66. (New) The method of claim 51, wherein determining the reduced expression of the mammalian 15 kDa selenoprotein comprises determining whether the expression of the mammalian 15 kDa selenoprotein is reduced by at least 5-fold in the cell of the subject when compared to expression of the 15 kDa selenoprotein in a control cell.
 - 67. (New)\The method of claim 51, wherein the cancer is a prostate cancer.
 - 68. (New) The method of claim 51, wherein the cancer is a liver cancer.
- 69. (New) The method of claim 51, wherein the cancer is a lymphoma, ovarian cancer, or fallopian tube cancer.
- 70. (New) The method of claim 51, wherein determining expression of the mammalian 15 kDa selenoprotein comprises contacting a sample comprising the cell of the subject with a specific binding agent that specifically binds to the mammalian 15 kDa selenoprotein under conditions whereby the specific binding agent forms a complex with any 15 kDa selenoprotein present in the sample, and quantifying the complexes.
- 71. (New) The method of claim 70, wherein the sample is a biological fluid or a biopsy sample.

WDN:SLR 09/03/02 137151.doc PATENT



- 72. (New) The method of claim 71, wherein the biological fluid is blood.
- 73. (New) The method of claim 70, wherein the specific binding agent that specifically binds to the mammalian 15 kDa selenoprotein is an antibody.
 - 74. (New) The method of claim 71, wherein the antibody is a polyclonal antibody.
 - 75. (New) The method of claim 72, wherein the antibody is a monoclonal antibody.
- 76. (New) The method of claim 73, wherein the monoclonal antibody is a humanized monoclonal antibody.
 - 77. (New) The method of claim 71, wherein the antibody is bound to a solid substrate.
- 78. (New) The method of claim 51, wherein determining expression of the mammalian 15 kDa selenoprotein comprises:

incubating ⁷⁵Se with the cell of the subject; and detecting ⁷⁵Se incorporated into the mammalian 15 kDa selenoprotein.

- 79. (New) The method of claim 78, wherein incubating ⁷⁵Se with the cell of the subject comprises administering the ⁷⁵Se to the subject.
- 80. (New) The method of claim 51, wherein determining expression of the mammalian 15 kDa selenoprotein comprises Western blotting of the mammalian 15 kDa selenoprotein, Northern blotting of an mRNA coding for the mammalian 15 kDa selenoprotein, or Southern blotting of a DNA encoding for the mammalian 15 kDa selenoprotein.
 - 81. (New) The method of claim 51, wherein the cell of the subject is a blood cell.
- 82. (New) The method of claim 51, wherein the cell of the subject is a thyroid or prostate cell.

Remarks

Claims 1-26, 29-34 and 36-65 were pending in the present application. Claims 1-26, 29-34, 36-50, 54, 56-59, 61-62 and 65 are cancelled. Claims 51-53, 55, 60, and 63-64 are amended. Claims 66-82 are added. Therefore, claims 51-53, 55, 60, 63-64 and 66-82 are now pending.

Claims 51-53 and 63-64 were amended due to the cancellation of claim 18, and to clarify the claims. Support can be found on page 3, lines 1-4 and page 36, lines 3-5 and 18-21;